Trials of PD-1 and PD-L1 inhibitors have demonstrated efficacy in solid tumors (21, 72), and clinical trials of PD-1 and PD-L1 inhibitors are currently underway in AML (Table 1). Here, CD274 is linked to acute myeloid leukemia.